ABOUT OUR COMPANY
BC Neuroimmunology began as the UBC Neuroimmunology Laboratory in 1984 under the directorship of Dr. Joel Oger. Dr. Oger was a professor of Neurology and had a keen interest in providing specialized services for patients affected with Neuro-Immunological disorders. After Dr. Oger’s retirement at the end of 2014, Dr. Hans Frykman took over the directorship of the laboratory. In 2019, it was established as a private company and rebranded as BC Neuroimmunology.
BC Neuroimmunology strives for excellence and specializes in developing and providing best-in-class diagnostic tests and high quality laboratory services in neuroimmunology and neurodegeneration to all across North America for clinical and research purposes. The laboratory is accredited by the College of Physicians and Surgeons of British Columbia’s Diagnostic Accreditation Program (DAP) and the College of American Pathologists (CAP).
We also provide support for human immune testing in clinical trials including Myasthenia Gravis and other neurological disorders.
For more information about testing, please contact our laboratory at email@example.com or 604-822-7175.
We provide a full panel for myasthenia gravis diagnostic testing, which includes AchR Ab, MuSK Ab, and LRP4 Ab, using multiple laboratory techniques. We employ an orthogonal algorithmic approach to ensure the highest degree of confidence in diagnosis.
Our testing for autoimmunce encephalitis includes antibodies to NMDAR, AMPAR, GABAB, LGI1, CASPR2, and DPPX as a panel or as individual tests. We utilize both fixed cell-based assays and immunohistological techniques to deliver the best possible results for diagnosis.
We provide diagnostic testing for neuromyelitis optica with AQP4 Ab and MOG Ab testing by live cell-based assay. BC Neuroimmunology is presently the only organization to offer live cell-based assay for AQP4 Ab in Canada.
CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Our antibody screen for CIDP employs a fixed cell-based assay (CBA) and can detect NF140, NF155, NF186, CNTN1, and CASPR1 antibodies with high specificity. Early diagnosis is crucial to prevent axonal degeneration and permanent damage.